Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives $24.71 Consensus PT from Analysts

Key Points

• Teva Pharmaceutical Industries Ltd. has received a consensus "Buy" rating from eight analysts, with an average target price of $24.71.
• In its latest quarterly earnings, Teva reported earnings per share of $0.66, surpassing analyst expectations but underperforming in revenue with $4.18 billion reported against a $4.34 billion forecast.
• Insider trading activity included significant sales, with one insider selling over 52,000 shares at an average price of $15.16 per share.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) has been assigned a consensus recommendation of "Buy" from the eight research firms that are currently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $24.7143.

Several equities analysts have weighed in on the stock. Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a "buy" rating and a $25.00 price objective on the stock. UBS Group lowered their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. The Goldman Sachs Group initiated coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a "buy" rating and a $24.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA traded down $0.07 during mid-day trading on Friday, reaching $18.38. 7,435,534 shares of the company's stock traded hands, compared to its average volume of 9,410,089. Teva Pharmaceutical Industries has a 12 month low of $12.47 and a 12 month high of $22.80. The stock has a market capitalization of $21.08 billion, a P/E ratio of -114.88, a price-to-earnings-growth ratio of 1.07 and a beta of 0.72. The business's 50-day moving average price is $17.51 and its 200-day moving average price is $16.58. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. The firm had revenue of $4.18 billion for the quarter, compared to analysts' expectations of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm's quarterly revenue was up .3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Equities analysts predict that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the sale, the insider directly owned 6,774 shares of the company's stock, valued at approximately $102,693.84. The trade was a 47.19% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.49% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Osaic Holdings Inc. raised its position in shares of Teva Pharmaceutical Industries by 17.4% during the second quarter. Osaic Holdings Inc. now owns 48,655 shares of the company's stock valued at $815,000 after buying an additional 7,223 shares during the last quarter. Orion Porfolio Solutions LLC raised its position in shares of Teva Pharmaceutical Industries by 23.1% during the second quarter. Orion Porfolio Solutions LLC now owns 12,474 shares of the company's stock valued at $209,000 after buying an additional 2,341 shares during the last quarter. Marex Group plc acquired a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at about $463,000. Advisory Services Network LLC raised its position in shares of Teva Pharmaceutical Industries by 11.9% during the second quarter. Advisory Services Network LLC now owns 47,737 shares of the company's stock valued at $738,000 after buying an additional 5,085 shares during the last quarter. Finally, State of Wyoming acquired a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at about $299,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.